Functional Improvement in Pulmonary Arterial Hypertension Patients Treated With Ivabradine
- 1 May 2014
- journal article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 20 (5) , 373-375
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure PatientsJACC, 2013
- Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?Clinical Research in Cardiology, 2013
- Ivabradine in systemic sclerosis related pulmonary arterial hypertensionEuropean Journal of Internal Medicine, 2012
- Ivabradine: potential clinical applications in critically ill patientsClinical Research in Cardiology, 2012
- Heart Rate-Lowering Efficacy and Respiratory Safety of Ivabradine in Patients with Obstructive Airway DiseaseAmerican Journal of Cardiovascular Drugs, 2012
- Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertensionClinical Research in Cardiology, 2012
- Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referralThe Journal of Heart and Lung Transplantation, 2012
- Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I f (funny channel current) inhibitor ivabradineClinical Research in Cardiology, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010